BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30716341)

  • 1. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia.
    Bashir B; Merlino DJ; Rappaport JA; Gnass E; Palazzo JP; Feng Y; Fearon ER; Snook AE; Waldman SA
    Hum Pathol; 2019 May; 87():103-114. PubMed ID: 30716341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
    Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
    Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing the intestinal GUCY2C tumor suppressor axis requires
    Pattison AM; Barton JR; Entezari AA; Zalewski A; Rappaport JA; Snook AE; Waldman SA
    Cancer Biol Ther; 2020 Sep; 21(9):799-805. PubMed ID: 32594830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
    O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
    Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
    Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
    Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease.
    Brenna Ø; Bruland T; Furnes MW; Granlund Av; Drozdov I; Emgård J; Brønstad G; Kidd M; Sandvik AK; Gustafsson BI
    Scand J Gastroenterol; 2015; 50(10):1241-52. PubMed ID: 25979109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
    Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
    Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
    Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
    Yan HHN; Lai JCW; Ho SL; Leung WK; Law WL; Lee JFY; Chan AKW; Tsui WY; Chan ASY; Lee BCH; Yue SSK; Man AHY; Clevers H; Yuen ST; Leung SY
    Gut; 2017 Sep; 66(9):1645-1656. PubMed ID: 27329244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
    Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
    Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.
    Rappaport JA; Entezari AA; Caspi A; Caksa S; Jhaveri AV; Stanek TJ; Ertel A; Kupper J; Fortina PM; McMahon SB; Jaynes JB; Snook AE; Waldman SA
    Cell Mol Gastroenterol Hepatol; 2022; 13(4):1276-1296. PubMed ID: 34954189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characteristics of serrated adenomas of the colorectum.
    Sawyer EJ; Cerar A; Hanby AM; Gorman P; Arends M; Talbot IC; Tomlinson IP
    Gut; 2002 Aug; 51(2):200-6. PubMed ID: 12117880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
    Rappaport JA; Waldman SA
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
    [No Abstract]   [Full Text] [Related]  

  • 15. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
    Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
    Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
    Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
    Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular differences between sporadic serrated and conventional colorectal adenomas.
    Konishi K; Yamochi T; Makino R; Kaneko K; Yamamoto T; Nozawa H; Katagiri A; Ito H; Nakayama K; Ota H; Mitamura K; Imawari M
    Clin Cancer Res; 2004 May; 10(9):3082-90. PubMed ID: 15131047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
    Kambara T; Simms LA; Whitehall VL; Spring KJ; Wynter CV; Walsh MD; Barker MA; Arnold S; McGivern A; Matsubara N; Tanaka N; Higuchi T; Young J; Jass JR; Leggett BA
    Gut; 2004 Aug; 53(8):1137-44. PubMed ID: 15247181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.
    Yamane LS; Scapulatempo-Neto C; Alvarenga L; Oliveira CZ; Berardinelli GN; Almodova E; Cunha TR; Fava G; Colaiacovo W; Melani A; Fregnani JH; Reis RM; Guimarães DP
    Oncol Rep; 2014 Oct; 32(4):1419-26. PubMed ID: 25050586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GUCY2C ligand replacement to prevent colorectal cancer.
    Blomain ES; Pattison AM; Waldman SA
    Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.